What is GenuIN Biotech?
GenuIN Biotech is a specialized provider of validated antibodies and associated research products, leveraging advanced knockdown and knockout techniques to guarantee dependable outcomes for scientific endeavors. Their comprehensive product portfolio encompasses KD-validated monoclonal antibodies, lentiviral particles, cell lines, and a variety of essential reagents. Furthermore, GenuIN Biotech extends its expertise through custom services, including the development of monoclonal antibodies and rigorous antibody validation processes. The company primarily serves researchers and laboratories that require high-quality, validated tools for precise gene silencing and in-depth protein analysis, aiming to accelerate discovery in the life sciences.
How much funding has GenuIN Biotech raised?
GenuIN Biotech has raised a total of $23K across 1 funding round:
Debt
$23K
Debt (2021): $23K with participation from PPP
Key Investors in GenuIN Biotech
PPP
Public-Private Partnership
What's next for GenuIN Biotech?
With the recent influx of substantial expansion capital, GenuIN Biotech is poised for significant advancements. This funding is expected to fuel the scaling of its production capabilities, enhance its research and development initiatives for novel antibody technologies, and potentially expand its service offerings. The company's strategic focus on validated tools for gene silencing and protein analysis suggests a continued commitment to supporting critical research in areas such as oncology, neuroscience, and immunology. Future developments may include strategic partnerships or further investment rounds to solidify its market position as a leading supplier of high-integrity biological reagents.
See full GenuIN Biotech company page
